See the DrugPatentWatch profile for Vidaza
When did the core Vidaza patent expire?
The primary patent covering Vidaza’s active ingredient, azacitidine (US 7,590,076), expired in 2018. A separate formulation patent (US 8,761,200) that protects the drug’s specific dosage form ran through 2020. After those dates, the exclusive rights that once protected Vidaza’s composition and delivery were lost.
What does this mean for generic entry?
Once a patent expires, generic manufacturers can file for approval, provided they meet FDA requirements for bioequivalence. The first generic azacitidine product in the U.S. is expected to reach the market in 2024, pending FDA review and any potential litigation.
Are there still patents that could delay generics?
Yes. Sanofi holds newer patents that cover certain manufacturing processes and formulations of azacitidine. These patents are set to expire between 2026 and 2030, giving the company a limited window to protect specific product versions or new delivery methods.
How might pricing change once generics are available?
Historically, generic entry has driven prices down by 50‑70 %. For Vidaza, insurers and pharmacy benefit managers anticipate a significant drop in acquisition costs, which could shift treatment patterns toward the cheaper generic.
Which companies are preparing to launch a generic?
Major generic players such as Teva, Mylan (now Viatris), and Sandoz have announced plans to develop azacitidine generics. They are preparing for FDA filings now that the key patents have lapsed.
Will the FDA approve a generic before the remaining patents expire?
The FDA’s approval process typically takes 12–18 months. If a generic file is submitted early enough, it can clear review before the latest process patents expire, allowing the generic to enter the market while the company still owns those patents.
What about international markets?
In many countries, the original Vidaza patents have expired earlier, and generics are already on the market. However, some regions still have active patents, so generic availability varies globally.
Does Vidaza still hold any market exclusivity beyond patents?
Beyond patents, Vidaza benefits from 12 years of data exclusivity that ended in 2016, and from a 5‑year exclusivity period that was granted in 2012 for a new indication (AML). Those exclusivities also concluded, leaving only the remaining process and formulation patents.
Where can I check the most recent patent status?
The DrugPatentWatch database lists the current status of all Vidaza‑related patents. The page provides expiry dates, legal status, and links to the full patent documents: https://www.drugpatentwatch.com/patents/azacitidine.
Sources
[1] https://www.drugpatentwatch.com/patents/azacitidine.